CL2021001297A1 - Anticuerpos antiperiostina y usos de estos - Google Patents
Anticuerpos antiperiostina y usos de estosInfo
- Publication number
- CL2021001297A1 CL2021001297A1 CL2021001297A CL2021001297A CL2021001297A1 CL 2021001297 A1 CL2021001297 A1 CL 2021001297A1 CL 2021001297 A CL2021001297 A CL 2021001297A CL 2021001297 A CL2021001297 A CL 2021001297A CL 2021001297 A1 CL2021001297 A1 CL 2021001297A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- antiperiostin
- periostin
- tumors
- modifying
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen en la presente anticuerpos que bloquean la función de la periostina. También se describen en la presente sus usos para tratar el cáncer y modificar las propiedades inmunitarias de los tumores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862779996P | 2018-12-14 | 2018-12-14 | |
US201962899075P | 2019-09-11 | 2019-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021001297A1 true CL2021001297A1 (es) | 2022-01-07 |
Family
ID=71075443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001297A CL2021001297A1 (es) | 2018-12-14 | 2021-05-18 | Anticuerpos antiperiostina y usos de estos |
Country Status (21)
Country | Link |
---|---|
US (1) | US20220010003A1 (es) |
EP (1) | EP3894439A4 (es) |
JP (2) | JP2022513228A (es) |
KR (1) | KR20210108972A (es) |
CN (1) | CN113631571A (es) |
AU (1) | AU2019395887A1 (es) |
BR (1) | BR112021010634A2 (es) |
CA (1) | CA3120059A1 (es) |
CL (1) | CL2021001297A1 (es) |
CO (1) | CO2021007444A2 (es) |
CR (1) | CR20210310A (es) |
DO (1) | DOP2021000113A (es) |
EC (1) | ECSP21043288A (es) |
IL (1) | IL283890A (es) |
JO (1) | JOP20210144A1 (es) |
MA (1) | MA54472A (es) |
MX (1) | MX2021007043A (es) |
PE (1) | PE20211962A1 (es) |
SA (1) | SA521422250B1 (es) |
SG (1) | SG11202103849TA (es) |
WO (1) | WO2020121059A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3148291A1 (en) * | 2019-09-11 | 2021-03-18 | Boehringer Ingelheim Io Canada, Inc. | Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies |
KR20240038198A (ko) | 2022-09-15 | 2024-03-25 | 한남대학교 산학협력단 | 인슐린 분비 베타세포 분화 유도 항체 및 이를 유효성분으로 포함하는 대사성 질환 예방 또는 치료용 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
EP2180007B2 (en) | 1998-04-20 | 2017-08-30 | Roche Glycart AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2007096142A2 (en) * | 2006-02-22 | 2007-08-30 | Philogen Spa | Vascular tumor markers |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
EP2757376A4 (en) * | 2011-09-15 | 2015-05-27 | Univ Nagoya Nat Univ Corp | MOLECULAR MARKER FOR EARLY IDENTIFICATION OF PATIENTS WITH PLEURAL MESOTHELIOMA AND RELATED EXPRESSION ANALYSIS METHOD |
JP6218088B2 (ja) * | 2013-03-08 | 2017-11-01 | 国立大学法人大阪大学 | ペリオスチンのExon−21部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物 |
RU2748401C2 (ru) * | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
-
2019
- 2019-12-13 CN CN201980082813.0A patent/CN113631571A/zh active Pending
- 2019-12-13 US US17/413,094 patent/US20220010003A1/en active Pending
- 2019-12-13 MX MX2021007043A patent/MX2021007043A/es unknown
- 2019-12-13 CA CA3120059A patent/CA3120059A1/en active Pending
- 2019-12-13 EP EP19897138.4A patent/EP3894439A4/en active Pending
- 2019-12-13 WO PCT/IB2019/001307 patent/WO2020121059A1/en unknown
- 2019-12-13 MA MA054472A patent/MA54472A/fr unknown
- 2019-12-13 KR KR1020217022051A patent/KR20210108972A/ko unknown
- 2019-12-13 AU AU2019395887A patent/AU2019395887A1/en active Pending
- 2019-12-13 JP JP2021534246A patent/JP2022513228A/ja active Pending
- 2019-12-13 PE PE2021000873A patent/PE20211962A1/es unknown
- 2019-12-13 CR CR20210310A patent/CR20210310A/es unknown
- 2019-12-13 JO JOP/2021/0144A patent/JOP20210144A1/ar unknown
- 2019-12-13 SG SG11202103849TA patent/SG11202103849TA/en unknown
- 2019-12-13 BR BR112021010634A patent/BR112021010634A2/pt unknown
-
2021
- 2021-05-18 CL CL2021001297A patent/CL2021001297A1/es unknown
- 2021-06-08 CO CONC2021/0007444A patent/CO2021007444A2/es unknown
- 2021-06-10 IL IL283890A patent/IL283890A/en unknown
- 2021-06-11 DO DO2021000113A patent/DOP2021000113A/es unknown
- 2021-06-13 SA SA521422250A patent/SA521422250B1/ar unknown
- 2021-06-14 EC ECSENADI202143288A patent/ECSP21043288A/es unknown
-
2023
- 2023-07-27 JP JP2023122675A patent/JP2023139243A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3894439A4 (en) | 2022-11-30 |
MX2021007043A (es) | 2021-08-11 |
CR20210310A (es) | 2021-11-24 |
JP2022513228A (ja) | 2022-02-07 |
US20220010003A1 (en) | 2022-01-13 |
SG11202103849TA (en) | 2021-05-28 |
EP3894439A1 (en) | 2021-10-20 |
CA3120059A1 (en) | 2020-06-18 |
BR112021010634A2 (pt) | 2021-11-16 |
JP2023139243A (ja) | 2023-10-03 |
CO2021007444A2 (es) | 2021-09-30 |
PE20211962A1 (es) | 2021-10-04 |
KR20210108972A (ko) | 2021-09-03 |
DOP2021000113A (es) | 2021-09-30 |
AU2019395887A1 (en) | 2021-05-20 |
SA521422250B1 (ar) | 2023-12-21 |
WO2020121059A1 (en) | 2020-06-18 |
ECSP21043288A (es) | 2021-09-30 |
JOP20210144A1 (ar) | 2023-01-30 |
IL283890A (en) | 2021-07-29 |
CN113631571A (zh) | 2021-11-09 |
MA54472A (fr) | 2022-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020014345A2 (es) | Anticuerpos específicos para gucy2c y sus usos | |
CO2019013010A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
CL2019002461A1 (es) | Arn terapéutico. | |
CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
UY37870A (es) | Inhibidores de kras g12c y métodos para utilizarlos campo de la invención | |
CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
CL2020003028A1 (es) | Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos. | |
CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
CL2019001646A1 (es) | Anticuerpos anti-ox40 y sus usos. | |
CO2018012699A2 (es) | Anticuerpos anti-cd40 y sus usos | |
ECSP19054235A (es) | Conjugados de fármacos y anticuerpos anticcr7 | |
CL2018002810A1 (es) | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada. | |
BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
ECSP21043288A (es) | Anticuerpos antiperiostina y usos de estos | |
CL2018001252A1 (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton | |
SV2016005352A (es) | Anticuerpos antagonistas del interferon alfa y omega | |
CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
CL2021000950A1 (es) | Anticuerpos contra el lif y usos de los mismos (divisional de la solicitud no. 201901717) | |
CO2018008249A2 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b | |
CO2023010689A2 (es) | Anticuerpos y usos de estos | |
CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
CO2021014351A2 (es) | Derivados de quinolina y su uso para el tratamiento del cáncer | |
CO2022003324A2 (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares |